eligibility_summary
Adults 18–75 with WHO 2016 DLBCL and measurable disease (Lugano 2014), relapsed/refractory after ≥1 systemic regimen incl anti‑CD20, ECOG 0–2, life expectancy >12 wks, adequate marrow/renal/hepatic function (ANC ≥1000/μL, Hgb ≥8 g/dL, PLT ≥100k, bilirubin ≤1.5×ULN, ALT/AST/ALP ≤2.5×ULN, ≤5× if liver involved). Exclude pregnancy, CNS/transformed lymphoma, active cancers, uncontrolled comorbidities or infections, disallowed recent therapies (incl CAR‑T <3 mo), QT‑prolonging/CYP3A4 drugs, recent trials, or investigator concern.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase Ib, open-label trial in relapsed/refractory DLBCL evaluating BEBT-908 (CUDC-908) alone or with rituximab, R-GemOx, or R-ICE. BEBT-908: IV small-molecule dual PI3K/HDAC inhibitor, blocks PI3K→AKT/mTOR signaling and HDACs to alter chromatin/transcription, suppress survival/proliferation, and induce apoptosis in lymphoma cells. Rituximab: anti-CD20 monoclonal antibody depleting CD20+ B cells via ADCC/CDC/apoptosis. Gemcitabine: antimetabolite inhibiting DNA synthesis. Oxaliplatin/Carboplatin: platinum agents causing DNA crosslinks. Ifosfamide: alkylator causing DNA crosslinks. Etoposide: topoisomerase II inhibitor causing DNA breaks. Targets: CD20+ malignant B cells, PI3K/AKT/mTOR and HDAC epigenetic pathways, DNA replication/repair and topo II in rapidly dividing lymphoma cells.